DeepCyte

Based in Copenhagen, Denmark, DeepCyte is a biotechnology company that develops artificial intelligence solutions utilizing single-cell metabolomics to detect, predict, and explain drug toxicity in individual human cells during preclinical testing. The organization operates the MetaCore platform, which enables high-throughput molecular profiling through a combination of laser-based sampling and mass spectrometry. Its initial commercial product, DeeImmuno, provides predictive toxicology specifically for immune cells and has demonstrated the ability to identify seventeen distinct toxicity mechanisms with 94% accuracy across tests on 100 different drugs. By revealing metabolic changes at a single-cell resolution, the enterprise provides these integrated software solutions to biopharmaceutical teams to reduce late-stage clinical trial failures. The firm is currently supported by $1.5 million in initial seed funding to commercialize its proprietary academic research. DeepCyte was officially founded in 2024 by Theodore Alexandrov.